2-210595535-G-C
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_001875.5(CPS1):āc.1312G>Cā(p.Ala438Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000548 in 1,459,714 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 12/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A438T) has been classified as Pathogenic.
Frequency
Consequence
NM_001875.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CPS1 | NM_001875.5 | c.1312G>C | p.Ala438Pro | missense_variant | 13/38 | ENST00000233072.10 | NP_001866.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CPS1 | ENST00000233072.10 | c.1312G>C | p.Ala438Pro | missense_variant | 13/38 | 1 | NM_001875.5 | ENSP00000233072.5 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000548 AC: 8AN: 1459714Hom.: 0 Cov.: 30 AF XY: 0.00000413 AC XY: 3AN XY: 726240
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Congenital hyperammonemia, type I Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | May 05, 2023 | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Experimental studies have shown that this missense change affects CPS1 function (PMID: 23649895). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on CPS1 protein function. ClinVar contains an entry for this variant (Variation ID: 449391). This missense change has been observed in individuals with carbamoyl phosphate synthetase deficiency (PMID: 17310273, 23649895; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces alanine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 438 of the CPS1 protein (p.Ala438Pro). - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 17, 2023 | Variant summary: CPS1 c.1312G>C (p.Ala438Pro) results in a non-conservative amino acid change located in the Carbamoyl-phosphate synthase large subunit, CPSase domain (IPR005483) of the encoded protein sequence. Four of four in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 250618 control chromosomes (gnomAD). c.1312G>C has been reported in the literature in one individual affected with Carbamoylphosphate Synthetase I Deficiency (Kurokawa_2007). At least one publication reports experimental evidence evaluating an impact on protein function showing an almost undetectable level of enzyme activity and decreased thermostability (Diez-Fernandez_2013). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 29, 2017 | The A438P variant in the CPS1 gene has previously been reported in association with CPS1 deficiency in an individual who was also heterozygous for a second variant in CPS1, although the phase of these variants was not reported (Kurokawa et al., 2007). Functional analysis of A438P found that it is associated with significantly reduced enzyme activity (Diez-Fernandez et al., 2013). The A438P variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The A438P variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs at a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. In summary, we interpret A438P to be a likely pathogenic variant. - |
Pulmonary hypertension, neonatal, susceptibility to;C4082171:Congenital hyperammonemia, type I Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Nov 19, 2021 | - - |
Pulmonary hypertension, neonatal, susceptibility to Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | May 30, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at